The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis

Alberto Banzato, Gentian Denas, Giuseppe Lombardi, Ardi Pambuku, Alessandra Bianchi, Vittorio Pengo

Research output: Contribution to journalArticlepeer-review


Letter to the Editor Patients with a mechanical heart prosthesis require lifelong anticoagulation to prevent valve thrombosis that could lead to deleterious complications or even death. LMWH protocols have proven feasible and safe in most mechanical prosthesis bearers requiring an interruption of oral anticoagulation because of surgery. However, some patient populations have not been included in trials and might behave differently. To this end, we would like to present the case of a 56-year-old man with mechanical aortic prosthesis treated with bevacizumab. His past medical history included aortic valve substitution for aortic stenosis, with a mechanical prosthesis, brain surgery for the excision of a single brain metastasis, and chemotherapy. In such a complicated scenery the choice of antithrombotic management in heart valvebearers should be individually tailored, taking into consideration the patient and antineoplastic therapy characteristics. Given the lack of evidence and of specific guidelines, patients with a mechanical heart valve should receive a strict control to avoid thrombotic complications.

Original languageEnglish
Pages (from-to)522-524
Number of pages3
JournalJournal of Heart Valve Disease
Issue number4
Publication statusPublished - Jul 2016


  • Journal Article


Dive into the research topics of 'The Three Players of Mechanical Valve Thrombosis: Cancer, Anticancer Therapy, and Thromboprophylaxis'. Together they form a unique fingerprint.

Cite this